Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Cyclopeptides

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514002000 - Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514011000 Monocyclic 158
514010000 Bicyclic 16
Entries
DocumentTitleDate
20090325863Somatostatin analogs and IGF-I inhibition for breast cancer prevention - The present invention relates generally to the use and application of compounds or agents, including somatostatin analogs, with effect on, affinity for, or specificity to SSTR3 and/or SSTR5 somatostatin receptors, particularly in the breast, for the treatment of breast hyperplasia, pre-neoplastic lesions and breast carcinoma and/or prevention or reduction of risk for breast cancer or treatment of breast cancer, including DCIS. The invention also relates to use of somatostatin analog SOM230 in treatment of breast hyperplasia and/or prevention or treatment of breast cancer. The invention includes assays and methods for screening and identifying breast hyperplasia with elevated SSTR3 and/or SSTR5 receptors and for chemotherapy and identifying compounds of use in the invention which are specific for, modulate via, or bind to SSTR3 and/or SSTR5 receptors.12-31-2009
20090023641Cyclic Antimicrobial Peptides - The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.01-22-2009
20090275499NONSTRUCTURAL PROTEIN NS1 AS A NOVEL THERAPEUTIC TARGET AGAINST FLAVIVIRUSES - The secretion or biological activity of Flaviviruses, as well as the biological activity of NS1 protein from Flavivirus-infected cells, can be inhibited by contacting the cells or the protein with cholesterol inhibitors, sphingolipid inhibitors, glycosphingolipid inhibitors, or molecules comprising an amphipathic, amphiphilic, or hydrophobic region which interacts with NS1 protein.11-05-2009
20100137198PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION - A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.06-03-2010
20100075895Cyclic Natriuretic Peptide Constructs - Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I:03-25-2010
20090111741METHOD FOR TREATING AND/OR PREVENTING DRUG SEEKING BEHAVIOR - A dynorphin-A analog can be used for treatment, inhibition, and/or prevention of cocaine seeking behavior, and or the drug seeking behavior for a cocaine derivative or other structurally related substance. The dynorphin-A analog can be a cyclic dynorphin-A analog having sufficient systemic stability that crosses the blood-brain barrier so as to be active in the brain at kappa-opioid receptors (KOR) as an antagonist. Such activity at a KOR as an antagonist can be useful for cocaine management and reducing the desire, such as stress-related desires, for use of cocaine, crack, or the like. The KOR antagonist can be [N-benzylTyr04-30-2009
20100041590Compounds - The present invention relates to substituted 3-Aminopyrazole compounds of formula (I)02-18-2010
20100041589METHODS FOR PREPARING PURIFIED LIPOPEPTIDES - The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions. 02-18-2010
20090156471Use of anti-amyloid agents for treating and typing pathogen infections - A method of preventing or treating a pathogen infection in a subject is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an anti amyloid agent, thereby treating or preventing the pathogen infection in the subject.06-18-2009
20100105608Peptides and methods using same for diagnosis and treatment of amyloid-associated disease - Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.04-29-2010
20090124537Screening method for bone morphogenetic mimetics - Disclosed are methods for identifying agents which modulate the activity of bone morphogenetic protein-7. These methods for identifying agents utilize bone morphogenetic protein receptors, specifically the daf-4 receptor, and more specifically the extracellular domain of the daf-4 receptor. Agents identified by the methods are also described as well as compositions comprising the agents and methods of treating a subject using the agents or compositions.05-14-2009
20090305957PREPARATION OF BIODEGRADABLE POLYESTERS WITH LOW-BURST PROPERTIES BY SUPERCRITICAL FLUID EXTRACTION - The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for carrying out stepwise purification of the biodegradable polyester at multiple pressures or multiple temperatures, or both, are also provided. When the polyester is PLG, a purified PLG copolymer is obtained having a narrowed molecular weight distribution with respect to the unpurified polyester. The purified PLG copolymer can have a polydispersity index of less than about 1.7, less than about 2% monomers, and less than about 10% oligomers. The purified PLG copolymer can exhibit a reduced initial burst effect when incorporated into a controlled release formulation such as a flowable implant adapted to be injected into body tissues.12-10-2009
20100056430Treatment and Method for Eliminating or Reducing Foot Odor - A method of treating a person having a foot odor comprises administering an effective foot odor treatment amount of an antimicrobial preparation, such as Polymyxin B. Sulfate, Bacitracin Zinc, and an antimicrobial such as Miconazole Nitrate, terbinafine hydrochloride, undecylenic acid, tolnaftate, clotrimazole, or butenafine hydrochloride, to eliminate or reduce the symptoms of foot odor.03-04-2010
20090305954HISTIDINE-CONTAINING DIASTEREOMERIC PEPTIDES AND USES THEREOF - Diastereomeric peptides with a net positive charge greater than +1, and cyclic derivatives thereof, are provided, having at least 13 amino acid residues, comprising histidine and one or more hydrophobic amino acid residues, optionally esterified or amidated at the C-terminus and/or acylated at the N-terminus. The peptides may contain other amino acid residues including non-natural amino acids. The peptides are particularly useful in the treatment of cancer.12-10-2009
20090011977Novel Lipopeptides as Antibacterial Agents - The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.01-08-2009
20100022446Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.01-28-2010
20080207494Cyclosporin Compositions - Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant. These are useful in the treatment of dry eye disease.08-28-2008
20090082259DEUTERIUM-ENRICHED OCTREOTIDE - The present application describes deuterium-enriched octreotide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-26-2009
20090023642Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A - Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.01-22-2009
20090247452PHARMACEUTICAL FORMULATIONS FOR REDUCING PAIN - The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.10-01-2009
20100173833METHODS AND COMPOSITION FOR USE OF CYCLIC ANALOGUES OF HISTATIN - Provided are novel compositions and therapeutic methods for treating bacterial and fungal disease with cyclic analogues of histatin. The cyclic analogues of histatin are advantageously more potent but less toxic than currently used anti-microbial agents. In addition, compositions comprising the cyclic analogue with other anti-microbial agents such as azole compounds are disclosed.07-08-2010
20090305956Treatment of Ras-Expressing Tumors - The present invention provides compositions and methods for the treatment of /?αs-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).12-10-2009
20100099604PEPTIDIC AND NON PEPTIDIC LIGANDS FOR IMMUNODETECTION OF THE RECEPTOR FOR UROTENSIN - The use of opportunely modified specific ligands of the receptor for urotensin II (UTR) or antibodies (commercially available) raised against the same receptor as tools for the definition of both the differentiation and the prognosis of human prostate adenocarcinoma is described, moreover, the use of opportunely radiolabeled ligands for UTR in the definition of the extension of disease is also described.04-22-2010
20090099068ON-GROWTH INHIBITING COMPOUNDS - An on-growth inhibiting agent, for the inhibition and/or prevention of on-growth of biological organisms on objects or living beings, includes at least one cyclotide, and a suitable carrier medium. A plant extract containing a mixture of cyclotides is also usable.04-16-2009
20090221472Method for treating transplant rejection - Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-09-03-2009
20100087364TROPINE MODULATORS OF 5-HT3 RECEPTOR - The present invention relates to new tropine modulators of 5-HT3 receptor, pharmaceutical compositions thereof, and methods of use thereof.04-08-2010
20090291881COATINGS FOR DRUG DELIVERY DEVICES - A polymer coating for medical devices based on a polyolefin derivative. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The polymers include homo-, co-, and terpolymers having at least one olefin-derived unit and at least one unit derived from vinyl alcohol, allyl alcohol and derivatives thereof.11-26-2009
20080207493Compounds for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.08-28-2008
20090275498NOVEL PEPTIDES - The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.11-05-2009
20080312140Compositions and Methods for Preventing or Treating Hiv Infection - The present invention is directed to compositions and methods of preventing for treating a retroviral infection, more particularly an HIV (human immunodeficiency virus) infection, and even more particularly an HIV-1 infection. The compositions and methods involve molecules that mimic the active site of the human CD4 protein.12-18-2008
20080318842Cyclic Isodityrosine Derivatives - [Problems] To provide a novel cyclic isodityrosine derivative having a physiological effect. 12-25-2008
20080280819METHODS FOR PROMOTING HAIR GROWTH - This disclosure reveals that cyclic corticotrophin releasing factor (CRF) antagonist peptides (such as astressin B, its functional fragments, and their derivatives) induce hair growth and prevent hair loss in vivo. This important discovery enables, for instance, methods of promoting hair growth, and methods of treating hair loss (such as the hair loss that occurs normally in some individuals or that is the result of a health disorder or therapeutic treatment). Exemplary cyclic CRF antagonist peptides useful in the disclosed methods are provided throughout the disclosure.11-13-2008
20080287345Polymyxin derivatives and uses thereof - The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than three; and to a combination product comprising at least two such derivatives. The invention further relates to a method for treating, alleviating or ameliorating an infection in a subject, caused by a Gram-negative bacterium by administering a therapeutically effective amount of a derivative according to the present invention to said subject; to a method for sensitizing Gram-negative bacteria to an antibacterial agent by administering, simultaneously or sequentially in any order a therapeutically effective amount of said antibacterial agent and a derivative according to the present invention to said subject; to methods for developing novel antibiotics; for reducing the nephrotoxicity, for improving the pharmacokinetic properties of natural polymyxins and octapeptins; and for sensitizing clinically important bacteria to a host defence mechanism complement present in serum. Finally, the invention relates to a process for preparing such polymyxin derivatives.11-20-2008
20090264342COMPOSITIONS AND METHODS FOR ANTIBIOTIC POTENTIATION AND DRUG DISCOVERY - The present invention provides methods for identifying target genes whose partial or complete functional inactivation potentiates the activity of an antibiotic agent, e.g., a quinolone antibiotic. The invention further provides methods for identifying agents that modulate expression of target genes or that modulate activity of expression products of target genes. Agents identified according to various methods of the invention potentiate the activity of antibiotics such as quinolones, aminoglycosides, peptide antibiotics and β-lactams. Also provided are agents that suppress and/or retard resistance to antibiotics. The inventive methods provide potentiating agents and compositions comprising potentiating agents and antibiotics. Such agents and compositions can be used for inhibiting growth or survival of a microbial cell or of treating a subject suffering from or susceptible to a microbial infection.10-22-2009
20090305955Cyclopeptide with Anti-Cancer Activity Derived from Collagen Type IV - The present invention relates to a cyclopeptide characterized in that it comprises the YSNS amino acid sequence, and more particularly a cyclopentapeptide which forms a β-bend structure at the YSNS amino acids. In one specific embodiment, the cyclopeptide of the invention is capable of binding to the αVβ3-integrin. The application also claims the use of a cyclopeptide of the invention in the treatment of cancer, and more particularly in the treatment of the various forms of melanoma, and also in the manufacture of a medicament for treating cancer. Finally, the application describes the use of a cyclopeptide of the invention for inhibiting or reducing angiogenesis, and more particularly in tumours, and also in the manufacture of a medicament for inhibiting or reducing angiogenesis.12-10-2009
20100137196HISTONE DEACETYLASES, AND USES RELATED THERETO - The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo.06-03-2010
20100137197LYOPHILIZED ANTI-FUNGAL COMPOSITION - A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature T06-03-2010
20090137462PHARMACEUTICAL COMPOSITION COMPRISING CYCLIC SOMATOSTATIN ANALOGUES - The present invention describes parenteral pharmaceutical compositions comprising a somatostatin analogue and novel somatostatin analogues.05-28-2009
20090062184FINE PARTICULATE PREPARATION COMPRISING COMPLEX OF NUCLEIC ACID MOLECULE AND COLLAGEN - The present invention relates an additive comprising at least one substance selected from arginine, trometamol, meglumine, lysine, histidine, monoethanolamine, diethanolamine, triethanolamine, succinic acid, citric acid, tartaric acid, lactic acid, and salts thereof, which is useful in the prevention of aggregation of fine particulate complexes of a nucleic acid and collagen, and the production of a preparation comprising particulate complexes of controlled size which is suited for transporting a nucleic acid into cells.03-05-2009
20080318843Device and Method for the Delivery of Drugs for the Treatment of Posterior Segment Disease - Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.12-25-2008
20100160213ANTIMICROBIAL AND ANTICANCER LIPOPEPTIDES - The invention provides lipophilic conjugates comprising a peptide coupled to a fatty acid, the peptide comprising at least two positively charged amino acid residues, said peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by pathogenic organisms such as bacteria and fungi. The lipophilic conjugates are also suitable for sanitation, as disinfectants, or for food preservation.06-24-2010
20090023640Use Of A Cyclic Undecapeptide For The Preparation Of A Medicament For Administration During Myocardial Ischaemic Events - The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.01-22-2009
20090062185DEUTERIUM-ENRICHED ANIDULAFUNGIN - The present application describes deuterium-enriched anidulafungin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-05-2009
20090082258Means and Methods for Treating Advanced Stage Neuroblastoma - The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of neuroblastoma. Moreover, the present invention encompasses methods of treatment for said diseases.03-26-2009
20090005294Peptides for the Treatment of Cancer Associated with the Human Papilloma Virus (HPV) and Other Epithelial Tumors - This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.01-01-2009
20090203583Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity - The present invention provides methods for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject, the method comprising administering to the subject a type-B lantibiotic. In particular, the invention provides methods for the treatment or prophylaxis of a 08-13-2009
20090203581Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.08-13-2009
20090197798COMPOSITION FOR TREATING CANCER AND USE THEREOF - The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.08-06-2009
20090105128CANNABINOID RECEPTOR TARGETED AGENT - Compounds of the following formula:04-23-2009
20090048156HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER - The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone resistant cancers to hormonal therapeutic agents. In particular embodiments, the present invention concerns delivery of a histone deacetylase inhibitor and a hormone targeted drug to an individual with cancer. In specific embodiments, the histone deacetylase inhibitor and the hormone targeted drug act synergistically to treat the cancer, including by overcoming resistance to a cancer therapy.02-19-2009
20100184647Use of Epinecidin-1 Peptides and Anti-lipopolysaccharide Factor Peptides for Treating Microbial Infection - Treatments of trichomonas, propionibacterium, or yeast infection using an epinecidin-1 peptide or an anti-lipopolysaccharide factor peptide.07-22-2010
20100184645STITCHED POLYPEPTIDES - The present invention provides inventive stitched polypeptides, pharmaceutical compositions thereof, and methods of making and using inventive stitched polypeptides.07-22-2010
20100113337METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS - A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to protect the skin of the subject from UVR-induced skin damage.05-06-2010
20090291879Modulation of cartilage homeostasis by active domains of cell binding extracelular matrix molecules - A linear or cyclic peptide and the use of said peptide in medicine and especially in the manufacture of a medicament for the treatment and/or prophylaxis of a disease associated with inflammatory mediated cartilage destruction. The minimal core sequence of the linear or cyclic peptide is WLEAK (SEQ ID No. 1). Alternatives are WLEAR and WLDAK.11-26-2009
20100222255PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME - Novel peptoid oligomers are disclosed that have a formula represented by the following formula I:09-02-2010
20100016219Ophthalmic compositions containing solubilized cyclosporin - An ophthalmic composition containing solubilized cyclosporin is able to be obtained in the presence of at least one 1,2-alkanediol having 5 to 7 carbon atoms and at least one polysorbate surface active agent in an ophthalmically acceptable medium. The composition is stable without crystallization and/or precipitation of cyclosporin. The composition is suitable for treatment of ophthalmic disorders including keratoconjectivis Sicca and ocular rosacea.01-21-2010
20100167993Compounds for Enhancing p21 Expression and Methods of Use Thereof - The present invention relates to a method for identifying a drug candidate for enhancing expression of p21ctpl/wafl in a human patient suffering from a medical condition that can be treated by enhancing expression of p21Cφl/wafl. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21ctpl/wafl promoter operationally ligated to a reporter domain; (b) exposing the cell line to a compound; and (c) identifying a compound that induces expression of the reporter domain. The compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cipl/wafl.07-01-2010
20090036361Use of Blood Coagulation Factor XIII for Treating Hemophilia A - A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.02-05-2009
20100144606COMBINATION 408 - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclohexyl-N06-10-2010
20090209456COMPOSITIONS AND METHODS FOR IMPROVING FACIAL AND BODY AESTHETICS - Compositions and methods of treating facial and body tissue aesthetics and reconstruction are disclosed using immunosuppressive agents either by themselves or in conjunction with other soft tissue fillers.08-20-2009
20100210516Growth Factor Binding Molecules - Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors.08-19-2010
20090305958STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF - The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or analog thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.12-10-2009
20100056431MEDICAL USES - The present invention provides the use of a polypeptide comprising an amino acid sequence according to SEQ ID NO: 1 (corresponding to the N-terminal 25 amino acid fragment of the human antimicrobial protein, LL-37) or a biologically active fragment, variant, fusion or derivative thereof, in the preparation of a medicament for the treatment of cancer. In particular, the inventions provides the use such polypeptides, or a fragment, variant, fusion or derivative thereof, to inhibit the proliferation and/or metastasis of cancer cells, such as breast cancer cells. The invention further comprises methods for the treatment of cancer in a patient.03-04-2010
20100056432TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY - Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 03-04-2010
20100056433Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.03-04-2010
20090215676Method of treatment - Disclosed is a method for attenuating the effects of growth hormone (GH) in a subject. The method comprises the administration of both a GH antagonist and a somatostatin agonist to said subject, simultaneously or separately, continuously or periodically. In one preferred embodiment of the method an extended release somatostatin agonist composition is administered monthly, and a conventional non-extended release GH antagonist composition is administered weekly.08-27-2009
20090215675Means for the inhibition of anti-beta1-adrenergic receptor antibodies - The present invention is related to a peptide selected from the group comprising a) a cyclic peptide of formula (I): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-x-x-x-Pro-x-Cys-Cys-xk-GIn), (I) whereby k is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably k=6; b) a cyclic peptide of formula (II): Cyclo(Ala-x-x-Trp-x-x-Gly-x-Phe-x-Cys-xh-Gln), (II) whereby h is any integer from 0 to 2, preferably 1 or 2; c) a cyclic peptide of formula (III): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-xj-Cys-x-x-x-Pro-x-Cys-Cys-xi-Gln); (HI) whereby j is any integer from 0 to 4, preferably j=4; whereby i is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably i−6; and d) a peptide of formula (IV): Ala-x1-Cys-xm-Cys-x-x-x-Pro-x-Cys-Cys-xn-Gln, (IV) whereby 1 is any integer from 0 to 9, preferably any integer from 1 to 9, more preferably n=9; whereby m is any integer from 0 to 4, preferably any integer from 1 to 4, more preferably m=4; whereby n is any integer from O to 6, preferably any integer from 1 to 6, more preferably n=6; whereby x is any amino acid, preferably any naturally occurring amino acid, more preferably any naturally occurring L-amino acid.08-27-2009
20090118167Selective Vpac2 Receptor Peptide Agonists - The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.05-07-2009
20090118168TOPICAL ADMINSTRATION OF ACYCLOVIR - The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a acyclovir compound. Methods of treatment, and methods of preparing the topical composition are also provided.05-07-2009
20080255036SUBSTITUTED THIOPHENES - Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.10-16-2008
20100120668METHOD OF TREATMENT OF PHOTODERMATOSES - A method for prophylactic or therapeutic treatment of photodermatoses that are caused or exacerbated by or associated with UVR exposure in a subject, particularly a human subject, which comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to reduce the photosensitivity of the skin of the subject.05-13-2010
20090170753CAPSOFUNGIN FORMULATIONS - The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable salt of caspofungin as active ingredient being useful for the prevention and/or treatment of fungal infections. Said compositions additionally comprise specific bulking agents and small amounts or no amounts of an additional pH modifier and may be in a liquid or solid form, e.g. may be lyophilized compositions. Said compositions show good stability and reduced amounts of sub-visible particulate matter formed in solutions which are reconstituted from the lyophilized product.07-02-2009
20100022447COMPOSITION FOR TREATING CANCER AND USE THEREOF - The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.01-28-2010
20100022445BIOLOGICALLY ACTIVE PEPTIDES - A peptide or peptide derivative comprising: 01-28-2010
20100234283IMMUNOGENIC EPITOPES, PEPTIDOMIMETICS, AND ANTI-PEPTIDE ANTIBODIES, AND METHODS OF THEIR USE - Provided herein are compositions and methods for the treatment of cancers. The compositions comprise at least one VEGF peptide mimic, HER-2 epitope, immunogenic VEGF peptides, and HER-2 immunogenic epitopes. The peptides and epitopes may be linear, cyclized, retro-inverso, or a combination of such forms. Also provided herein are antibodies raised to VEGF peptide mimics, HER-2 epitopes, immunogenic VEGF peptides, and HER-2 immunogenic epitopes.09-16-2010
20100184646MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN - The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.07-22-2010
20090325862Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration - The instant invention is directed to methods for treating neurodegenerative diseases comprises administering an effective amount of a selective histone deacetylase 8 inhibitor to a patient in need thereof.12-31-2009
20090291880METHODS COMPRISING DESMOPRESSIN - The present disclosure is directed to gender, age, and dose effects of desmopressin on reducing nocturnal voids, increasing an initial period of undisturbed sleep, and/or reducing nocturnal urine volume.11-26-2009
20090186809USE OF VALPROIC ACID FOR THE TOPICAL TREATMENT OF MILD TO MODERATE ACNE VULGARIS - The present invention provides a surprising therapeutic beneficial use for the topical application of valproic acid as a single agent therapy for patients suffering from mild to moderate acne vulgaris. Topically applied VPA has a clinical efficacy comparable to that of the marketed standard medication for this indication, isotretinoin. Furthermore, topically applied VPA is on average well to very well tolerated. The invention relates to the topical medical use of VPA for the treatment of acne vulgaris and comprises the topical application of VPA or of a pharmaceutically acceptable salt thereof.07-23-2009
20090197799METHODS FOR PREPARING PURIFIED LIPOTIDES - The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.08-06-2009
20100152099MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA - The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.06-17-2010
20100093610ROMIDEPSIN-BASED TREATMENTS FOR CANCER - The invention provides an improved process for preparing romidepsin. The process involves producing, purifying, or storing romidepsin under conditions that prevent the formation of undesired adducts. Purifying romidepsin at an apparent pH lower than approximately 6.0 (e.g., between an apparent pH of 4.0 and 6.0) has been discovered to prevent the reduction of the disulfide bond of romidepsin and the subsequent formation of dimerized, oligomerized, or polymerized adducts. The invention also provides pharmaceutical compositions of monomeric romidepsin free of dimerized, oligomerized, or polymerized adducts.04-15-2010
20080214445Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib - The invention relates to a method of treating a warm-blooded animal having a solid tumor disease comprising administering a combination which comprises (a) a N-phenyl-2-pyrimidine-amine derivative, especially N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.09-04-2008
20100173832ANTICANCEROUS POLYMERIC AGENTS - Methods and pharmaceutical compositions for treating cancer, particularly MDR cancer, which utilize polymeric compounds that are composed of a plurality of amino acid residues and one or more hydrophobic moieties are disclosed.07-08-2010
20100173834CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS - The present invention is directed to compounds according to formula, (R07-08-2010
20100210515METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS - The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.08-19-2010
20100048461METHODS OF USE OF TRK RECEPTOR MODULATORS - The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise β-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.02-25-2010
20100048460SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.02-25-2010
20100048462TRUNCATED PTH PEPTIDES WITH A CYCLIC CONFORMATION - The present invention provides PTH peptides which are cyclised substitution analogues of the truncated PTH fragment PTH (1-17) and which preferably retain the desired or similar biological activity of human PTH (1-34).02-25-2010
20100048459LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM A. GARBADINENSIS AND A. LIGURIAE - This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterised biosynthetic gene clusters.02-25-2010
20080287346Bioactive peptides - The present invention provides a cytotoxic 7 to 25-mer peptide with three or more cationic residues which has one or more non-generic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and their use as medicaments, particularly as antibacterial or antitumor agents.11-20-2008
20100204089PHOSPHORYLATED PYRONE ANALOGS AND METHODS - The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents.08-12-2010
20100204088Cyclic Peptide Antitumor Agents - Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.08-12-2010
20100234284Pharmaceutical compositions based on NK2 antagonists for pediatric use - Pharmaceutical compositions containing NK2 antagonists are described, useful for the treatment of infantile colics.09-16-2010
20090215677POLYMYXIN DERIVATIVES AND USES THEREOF - The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than three; and to a combination product comprising at least two such derivatives. The invention further relates to a method for treating, alleviating or ameliorating an infection in a subject, caused by a Gram-negative bacterium by administering a therapeutically effective amount of a derivative according to the present invention to said subject; to a method for sensitizing Gram-negative bacteria to an antibacterial agent by administering, simultaneously or sequentially in any order a therapeutically effective amount of said antibacterial agent and a derivative according to the present invention to said subject; to methods for developing novel antibiotics; for reducing the nephrotoxicity, for improving the pharmacokinetic properties of natural polymyxins and octapeptins; and for sensitizing clinically important bacteria to a host defense mechanism complement present in serum. Finally, the invention relates to a process for preparing such polymyxin derivatives.08-27-2009
20090163405Angiogenic peptides and uses thereof - A peptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, 4, 6, 8, 10 or 12 is provided. The peptide being at least 6 and no more than 50 amino acid residues in length. Also provided are therapeutic applications using such peptides.06-25-2009
20100069294HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.03-18-2010
20080234182BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES - This invention provides a new generalized method for screening, identifying, selecting and designing symmetry-based compounds useful for blocking pores or prepores formed by pathogenic agents including bacteria, viruses, fungi, parasites, and other proteins capable of forming pores on cellular membranes as a step in the pathogenic mechanism of the agent. Also provided are pharmaceutical compositions, filtering devices, and treatment methods useful for preventing, delaying, or otherwise altering the pathogenesis of the pore-forming pathogenic agents.09-25-2008
20080227693Cyclic Peptide Isolation by Spray Drying - Methods for isolation of a synthetic cyclic peptide by spray drying, including spray drying at elevated temperatures, products made by the methods, and synthetic cyclic peptides preparations with defined characteristics, including an essentially amorphous acid addition salt of Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH in the form of a fine powder with a particle diameter of about 2 to about 20 microns.09-18-2008
20090203582LYSOBACTIN AMIDES - The invention relates to lysobactin amides and methods for their preparation, as well as their use for manufacturing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.08-13-2009

Patent applications in class Cyclopeptides

Patent applications in all subclasses Cyclopeptides